Back

Cilostazol induces regression of carotid plaque in patients with high cardiovascular risk: CLOVER study. A multicenter, randomized trial.

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Optimal surrogate endpoints of drug response Antiplatelet Drugs ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Kyoung Im Cho

Maryknoll Medical Center, Busan (Korea (Republic of))

5 More presentations in this session

Presentation thumbnail
The influence of sarcopenia on bleeding risk in patients with atrial fibrillation undergoing coronary stenting and subsequent triple antithrombotic therapy
Doctor K. Tsuchida (Niigata, JP)
Abstract Slides
Presentation thumbnail
Interaction of statin therapy to angiotensin ii receptor type 1 blockers in erectile dysfunction patients. effect on endothelial function and aortic stiffness
Doctor N. Ioakeimidis (Athens, GR)
Abstract Slides
Presentation thumbnail
Physiologically-based pharmacokinetic (PBPK) model predicted versus observed effect of Child Pugh mild and moderate hepatic impairment on betrixaban pharmacokinetics
Doctor J. Leeds (South San Francisco, US)
Abstract Slides
Presentation thumbnail
Acute and chronic effect of ticagrelor versus clopidogrel on aortic stiffness
Associate Professor C. Vlachopoulos (Athens, GR)
Abstract Slides
Presentation thumbnail
Ticagrelor reduced CD40L level in patient with ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention compared with clopidogrel
Doctor Z. Li (Jinan, CN)
Abstract Slides

Access the full session

Session thumbnail
Optimal surrogate endpoints of drug response

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources